Imugene Limited IMU.AX · Stock Open Imugene Limited in new tab
Imugene Limited Analysis (IMU.AX)
Is Imugene Limited a good investment? Imugene Limited (IMU.AX) is currently trading at 0.0410 AUD. Market analysts have a consensus price target of 0.31 AUD. This suggests a potential upside from current levels.
Earnings Schedule: Imugene Limited is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.06.
Investor FAQ
Does Imugene Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Imugene Limited?
Imugene Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.31.
Company Profile
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 9, 1996 | 1.01 |
| Jan. 30, 2002 | 1:5 |
| Nov. 12, 2002 | 0.13 |
| July 2, 2025 | 0.03 |
Community Discussion